Nasdaq · Healthcare
Organogenesis Holdings Inc. (ORGO)
As-reported financials and recent SEC filings for Organogenesis Holdings Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$564.2M
Net income
$37.0M
Net margin
6.6%
Diluted EPS
$0.15
ROE
12.3%
P/E (TTM)
16.2×
Market cap
$312.7M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $564.2M | $482.0M | $433.1M | $450.9M | $467.4M |
| Gross profit | — | $366.3M | $326.7M | $345.9M | $353.2M |
| Operating income | $44.7M | $-1.3M | $12.5M | $22.3M | $72.2M |
| Net income | $37.0M | $861,000 | $4.9M | $15.5M | $94.2M |
| Diluted EPS | $0.15 | $-0.01 | $0.04 | $0.12 | $0.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-16
View on EDGAR →10-Q2026-05-07
View on EDGAR →8-K2026-05-07
View on EDGAR →ARS2026-04-30
View on EDGAR →DEF 14A2026-04-30
View on EDGAR →42026-04-24
View on EDGAR →42026-03-11
View on EDGAR →42026-03-11
View on EDGAR →Go deeper on ORGO
Search Organogenesis Holdings Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.